Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
54
Phase 1 dose-finding study, the study design is for QN-302 to be given once a week, intravenously over 60 min, on Day 1, Day 8, and Day 15 of a 28-Day cycle.
HonorHealth
Scottsdale, Arizona, United States
RECRUITINGYale
New Haven, Connecticut, United States
NOT_YET_RECRUITINGSTART Midwest
Grand Rapids, Michigan, United States
RECRUITINGMD Anderson Cancer Center
Houston, Texas, United States
NOT_YET_RECRUITINGDetermine MTD
maximum tolerated dose identified from dose escalation cohorts
Time frame: 18 months
Establish RP2D
recommended Phase 2 dose identified from dose escalation cohorts
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.